CUSIP 61559X104CLASS A ORDMLTXQ4 2025
24 filings · latest Feb 17, 2026
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Bvf Inc/Il | 19.75M | $260.32M |
| 2 | Deep Track Capital, LP | 4.61M | $60.76M |
| 3 | Cormorant Asset Management, LP | 4.36M | $57.40M |
| 4 | D. E. Shaw & Co., Inc. | 2.48M | $32.70M |
| 5 | Janus Henderson Group PLC | 2.10M | $27.66M |
| 6 | Logos Global Management LP | 1.75M | $23.07M |
| 7 | Jane Street Group, LLC | 1.68M | $22.17M |
| 8 | Balyasny Asset Management L.P. | 1.57M | $20.71M |
| 9 |
| 4 | Nov 10, 2025 | Biotechnology Value Fund L P | 13D/A | 27.7% | — | SEC |
| 5 | Nov 5, 2025 | Fmr LLC | 13G/A | 1.1% | 726.9K | SEC |
| 6 | Oct 1, 2025 | Chen Bihua | 13G/A | 3.1% | 1.99M | SEC |
| 7 | Aug 14, 2025 | Avoro Capital Advisors LLC | 13G | 6.5% | 4.15M | SEC |
| 8 | Aug 6, 2025 | Fmr LLC | 13G/A | 9.0% | 5.70M | SEC |
| 9 | May 14, 2025 | T. Rowe Price Associates, Inc. | 13G/A | 4.7% | 2.97M | SEC |
| 10 | Feb 14, 2025 | T. Rowe Price Associates, Inc. | 13G | 5.3% | 3.34M | SEC |
See the full Schedule 13D/13G history for Moonlake Immunotherapeutics.
Unlock full history| Morgan Stanley |
| 1.04M |
| $13.77M |
| 10 | Vivo Capital, LLC | 1.00M | $13.18M |